47th week of 2010 patent applcation highlights part 34 |
Patent application number | Title | Published |
20100296997 | Method for creating high carbon content products from biomass oil - In a method for producing high carbon content products from biomass, a biomass oil is added to a cracking reactor vessel. The biomass oil is heated to a temperature ranging from about 100° C. to about 800° C. at a pressure ranging from about vacuum conditions to about 20,700 kPa for a time sufficient to crack the biomass oil. Tar is separated from the cracked biomass oil. The tar is heated to a temperature ranging from about 200° C. to about 1500° C. at a pressure ranging from about vacuum conditions to about 20,700 kPa for a time sufficient to reduce the tar to a high carbon content product containing at least about 50% carbon by weight. | 2010-11-25 |
20100296998 | REACTOR FOR PRODUCING CHLORINE AND PROCESS FOR PRODUCING CHLORINE - A rector for producing chlorine according to the present invention is a multi-tubular heat exchanger type reactor for use in producing chlorine by oxidizing hydrogen chloride with oxygen, characterized in that | 2010-11-25 |
20100296999 | Ozonated capacitive deionization process - Water from coal bed methane production which is suitable for almost nothing, is ozonated in a reactor to oxidize the iron content from +2 to +3, that is from ferrous to ferric, and to oxidize the manganese content from +2 to +4. The water after such first treatment is run through a separation means and then through a rotating filter, and then subjected to capacitive deionization, to yield clean water, which is then treated further to adjust he sodium content to render the water suitable for domestic and agricultural purposes. Some of the produced water is run back through the capacitive deionization cells when no voltage is applied to clean the cells for the next voltage application cycle. Some of the water produced may also be run back through the separation means to help clean out the crud. | 2010-11-25 |
20100297000 | Product water from an ozonated capacitive deionization process - Unsuitable water from coal bed methane production, CBMPW, is ozonated in a reactor to oxidize iron and the manganese content,—iron from ferrous to ferric, and the manganese from +2 to +4—and kill microbes and destroy other organic material. The water after such treatment is run through a separation means and then a rotating filter, followed by capacitive deionization, to yield clean water, which is treated further to adjust the sodium content to render the water suitable for domestic and agricultural purposes. Some product water is returned through the capacitive deionization cells when no voltage is applied to clean the cells for the next voltage application cycle, and some product water may also be run back through the separation means to help clean out the crud. This product water is suitable for irrigation and can depending on local law be used for drinking either without or with further treatment. | 2010-11-25 |
20100297001 | METHOD AND SYSTEM FOR PRODUCING INTEGRATED HYDROGEN FROM ORGANIC MATTER - A method for production of hydrogen from organic matter, includes: pyrolysis of a feed of organic matter by passing a gaseous treatment stream essentially having carbon dioxide through the organic matter, the pyrolysis producing, on the one hand, a pyrolysis gas stream having the gaseous treatment stream, steam and volatile organic compounds originating from the organic matter, and on the other hand pyrolysis chars having carbon components; oxycombustion of at least a proportion of the volatile organic compounds present in the pyrolysis gas stream, by injection of oxygen, upstream of a layer of redox filtering matter comprising high-temperature carbon components; and after the oxycombustion, passing the oxidized pyrolysis gas stream through the redox layer, the passage producing a synthesis gas stream comprising hydrogen obtained by deoxidation of steam by the high-temperature carbon components. | 2010-11-25 |
20100297002 | CRYSTALLIZED SILICON-CONTAINING MATERIAL WITH HIERARCHICAL AND ORGANIZED POROSITY - Material with hierarchical and organized porosity in the microporosity and mesoporosity domains, consisting of at least two elementary spherical particles, each one of said particles comprising a matrix based on silicon oxide, mesostructured, having a mesopore diameter ranging between 1.5 and 30 nm and exhibiting microporous and crystallized walls of thickness ranging between 1 and 60 nm, said elementary spherical particles having a maximum diameter of 200 microns. The preparation of said material is also described. | 2010-11-25 |
20100297003 | Anti-human tenascin monoclonal antibody - An anti-human tenascin monoclonal antibody is described, whose light and heavy chain variable region sequences are SEQ ID 1 and SEQ ID 2, respectively, its proteolytic fragments capable of binding to an antigenic epitope within the region A | 2010-11-25 |
20100297004 | HIGH AFFINITY ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES FOR CANCER TARGETING AND DETECTION - The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA. | 2010-11-25 |
20100297005 | NUCLEIC ACIDS AND CORRESPONDING PROTEIN ENTITLED 125P5C8 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 191P4D12(b) and its encoded protein, and variants thereof, are described wherein 191P4D12(b) exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 191P4D12(b) provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 191P4D12(b) gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P4D12(b) can be used in active or passive immunization. | 2010-11-25 |
20100297006 | NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 191P4D12(b) USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 191P4D12(b) and its encoded protein, and variants thereof, are described wherein 191P4D12(b) exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 191P4D12(b) provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 191P4D12(b) gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P4D12(b) can be used in active or passive immunization. | 2010-11-25 |
20100297007 | LIGAND DIRECTED TOROIDAL NANOPARTICLES FOR THERAPY AND DIAGNOSTIC IMAGING - The present invention provides nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to deliver therapeutic agents and/or imaging agents. | 2010-11-25 |
20100297008 | GANGLIOSIDE ASSOCIATED RECOMBINANT ANTIBODIES AND THE USE THEREOF IN THE DIAGNOSIS AND TREATMENT OF TUMORS - The present invention is related with the obtaining of modified antibodies by means of the DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3) produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026 and from its anti-idiotype murine monoclonal antibody 1E10 (MAbai 1E10) produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specific binding to the antigen of the original antibodies, but being at the same time less immunogenic. The chimeric antibodies of the invention contain the variable domains of the murine immunoglobulin and the constant regions of the human immunoglobulin; and those humanized, besides containing the constant regions of the human immunoglobulins, they are modified in the region of the murine frameworks (FRs) and in particular in those zones that could be in an antigenic site for the T cells, so several positions of the FRS are human as well. These antibodies can be used in the diagnosis and therapy of different types of tumors. The present invention is also related with use of the antibodies for therapeutical and diagnostic purposes. | 2010-11-25 |
20100297009 | SELF-ASSEMBLED POLYHEDRAL MULTIMERIC CHEMICAL STRUCTURES - Self-assembled, closed and hollow chemical multimer structures having a dodecahedral morphology, composed of chemical monomers having a structurally symmetric core which possess a 5-fold rotational symmetry, are provided. Also provided are methods of creating such chemical monomers, methods of creating such chemical multimer structures and compositions comprising these chemical multimer structures. Also provided are uses of these chemical multimer structures in applications such as drug delivery, imaging, immunization, formation of plastic crystals and nanoparticle matrices and other medical and material science applications. | 2010-11-25 |
20100297010 | TUMOR SUPPRESSOR GENE SCREENING USING RNA INTERFERENCE LIBRARIES AND METHOD OF TREATMENT - The present invention is directed to methods of identifying tumor suppressor genes in vivo, tumor suppressors thus found, methods of treatment taking advantage of the identified tumor suppressors, methods of and kits for diagnosis of cancer using the identified tumor suppressor, and pharmaceutical composition comprising an identified tumor suppressor or modulators thereof. | 2010-11-25 |
20100297011 | ISOLATED PEPTIDES AND USES THEREOF - The present invention provides isolated preproinsulin-derived peptides of 8 or 9 amino acids, comprising the amino acid sequence WGPDPAA (SEQ ID NO: 1), isolated Class I peptide-HLA complexes presenting said peptides and isolated molecules having binding affinity for said peptides and/or said peptide-HLA complexes. Such compositions are useful in the treatment of Type 1 diabetes mellitus (T1DM). | 2010-11-25 |
20100297012 | HUMANIZED ANTIBODY - The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system. | 2010-11-25 |
20100297013 | HUMANIZED ANTIBODY - The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system. | 2010-11-25 |
20100297014 | METHOD OF DETECTING THE RISK OF CANCER USING GENETIC MARKERS - An ex vivo method for the detection of the risk of cancer in a patient, comprising the step of:
| 2010-11-25 |
20100297015 | CANCER BIOMARKER AND USES THEREOF - A method of determining the cancer status of a subject, comprising the steps of (a) providing a sample of material obtained from a subject; (b) determining the level GTPCH in the sample; and (c) comparing the level determined in (b) with one or more reference values. | 2010-11-25 |
20100297016 | QUARTERNARY NITROGEN HETEROCYCLIC COMPOUNDS FOR DETECTING AQUEOUS MONOSACCHARIDES IN PHYSIOLOGICAL FLUIDS - Quaternary nitrogen heterocyclic boronic acid-containing compounds are described, which are sensitive to glucose and fructose, as well as a variety of other physiologically important analytes, such as aqueous chloride and iodide, and a method of using the compounds. Also disclosed is a contact lens doped with the quaternary nitrogen heterocyclic boronic acid-containing compound, and a method of using the doped contact lens to measure the concentration of analyte in tears under physiological conditions. | 2010-11-25 |
20100297017 | Method for Synthesizing and Using Pegylated Peptide-Photoactive Chromophore Conjugates and Micellular Formulations Thereof - The invention relates to a PEGylated peptide-chromophore conjugate, which forms irregular micelles, for use in photodiagnostic and phototherapeutic applications. Methods for synthesizing and using the conjugates of the invention are also provided. | 2010-11-25 |
20100297018 | Prognosis and therapy of liver failure - A method for assessing prognosis in an individual suffering from liver failure, which method comprises detecting endotoxin in the individual, for example by determining the neutrophil function in the individual. The method can be used to determine whether there is an increased risk of infection in the individual, an increased risk of organ failure in the individual, an increased risk of mortality in the individual and/or an increased risk that the individual will not respond positively to treatment with an immunosuppressive agent, a steroid or an antibiotic. | 2010-11-25 |
20100297019 | PARTICLES FOR IMAGING - The invention encompasses particles comprising metal atoms, methods of making the particles, and methods for using the particles. In particular, the particles may be used to image biological tissues or to deliver a bioactive agent. | 2010-11-25 |
20100297020 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT - Methods are described for the treatment and prevention of metabolic disorders or other diseases by administering a pyrone analog or a derivative thereof. Methods are also described for the treatment and prevention of metabolic disorders and other diseases by administering a pyrone analog, or a derivative thereof, in combination with one or more additional agents such as, for example, lipid lowering agents or glucose lowering agents. Methods are described for the modulation of lipid transporter activity to increase the efflux of lipid from a physiological compartment into an external environment. Methods disclosed herein may be used to assess treatment or prevention of a metabolic disorder following administration of a pyrone analog or a derivative thereof. | 2010-11-25 |
20100297021 | Variants of C-Type Natriuretic Peptide - The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis). | 2010-11-25 |
20100297022 | Magnetosome Gene Expression in Eukaryotic Cells - The invention is the production of magnetosome-like structures in cells. The invention provides in vitro and in vivo diagnostic and therapeutic methods using eukaryotic cells expressing magnetosome-like structures that act as contrast agents. | 2010-11-25 |
20100297023 | Lipid - The present invention provides a lipid of the formula (I) R | 2010-11-25 |
20100297024 | PROMOTER INDUCIBLE BY REACTIVE OXYGEN SPECIES AND VECTOR COMPRISING THE SAME - The invention provides promoters inducible by reactive oxygen species (ROS), capable of driving the expression of a gene of interest, particularly in a tumor cell. More particularly, it refers to promoters inducible by reactive oxygen species, that may be used to drive the expression of a gene of interest, such as a therapeutic gene, or a reporter gene for use in image diagnosis. The promoters comprise at least a fragment of a promoter sequence responsive to said reactive oxygen species, and corresponding to a gene highly expressed in cancer cells, wherein the fragment of the promoter sequence responsive to reactive oxygen species (ROS) is selected from the group of: the VE element of the VEGF promoter, the E6 element of the promoter of the EGR-1 gene, the MMP-1 element and a chimeric promoter containing an E6 element and a VE element. It also provides vectors carrying a human therapeutic or non therapeutic gene of interest, operably linked to said promoter sequence and compositions comprising the same. | 2010-11-25 |
20100297025 | Novel compositions magnetic particles covered with gem-bisphosphonate derivatives - The invention relates to a composition comprising acid magnetic particles (p) based on an iron compound, the acid magnetic particles (p) being complexed by one or more gem-bisphosphonate compounds, of formula I: | 2010-11-25 |
20100297026 | Imaging of Activated Vascular Endothelium Using Immunomagnetic MRI Contrast Agents - Immunomagnetic nanoparticles are used as a contrast agent for enhancing medical diagnostic imaging such as magnetic resonance imaging (MRI). The present invention is directed to methods of making targeted MRI contrast agents from immunomagnetic particles, and to methods of using such MRI contrast agents. Typically, such targeted MRI contrast agents provide enhanced relaxivity, improved signal-to-noise, targeting ability, and resistance to agglomeration. Methods of making such MRI contrast agents typically afford better control over particle size, and methods of using such MRI contrast agents typically can afford enhanced blood clearance rates and distribution. The ability to use the contrast agents im MRI provides a tool in the diagnosis and treatment of several disease states. | 2010-11-25 |
20100297027 | Overt authentication features for compositions and objects and methods of fabrication and verification thereof - Overt anti-counterfeiting features on objects and compositions, especially pharmaceutical compositions. In a preferred embodiment, a counterfeiting-proof overt feature that presents a visually distinctive optical variable or invariable effect is manufactured on a pharmaceutical composition using a purely physical process. Further preferred are counterfeiting-proof, overt features that comprise at least one engineered array of micro- or nanostructures. Also provided are methods and apparatus for the manufacturing of said overt features on said objects and compositions, including pharmaceutical compositions, and for verifying the authenticity of said features. The inventive features do not reside in the method of making the stamp or the instrument used for stamping. | 2010-11-25 |
20100297028 | MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES - The present invention relates to new medicament combinations which contain in addition to one or more, preferably one compound of general formula 1 | 2010-11-25 |
20100297029 | VIRUCIDAL COMPOSITION - The invention relates to a virucidal composition comprising based on the composition
| 2010-11-25 |
20100297031 | ORODISPERSIBLE TABLETS - This invention relates to a an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture, said mixture comprising up to 15% by weight of calcium silicate, at least 50% of a diluent, a disintegrant agent and an active ingredient. It also relates to a process for preparing the tablets by homogeneous blending the specific excipients in powder form and subsequent direct compression of the mixture. Said tablets disintegrate quickly in the cavity of the mouth, in particular in less than 15 seconds. | 2010-11-25 |
20100297032 | TRANSDERMAL DELIVERY SYSTEM - A transdermal delivery system comprising a composition comprising a physiologically active agent and a penetration enhancer wherein the penetration enhancer comprises a combination of (i) an ester of salicylic acid, preferably selected from the C | 2010-11-25 |
20100297033 | Megaribavirin alone or combination of other antiviral, antioxidant and a perflubron emulsion for treatment of viral disease - The present invention is a novel method using a MegaRibavirin aerosol or a MegaRibavirin combination of therapeutics for the treatment of viral disease particularly the pandemic influenza strains “swine” 2009 H1N1 and H5N1. This invention utilizes Ribavirin in an aerosol Mega Dose (61-161 mg/ml) alone or combined with or without other antivirals, a perfluorocarbon emulsion and anti-inflammatory/anti-oxidants. Where applicable, the perfluorocarbon emulsion may dissolve these agents enabling a depot effect and possible protracted delivery. In addition perfluorocarbon emulsions have the possible added benefit of oxygen carrying capacity and alveolar nitric oxide sequestration, which may reduce peroxynitrite formation and decrease Influenza severity. | 2010-11-25 |
20100297034 | OSMOLYTE-CONTAINING PREPARATION FOR USE IN CASE OF DRY MUCOUS MEMBRANES - The present invention relates to osmolyte-containing preparations for the local treatment of dry mucous membranes. It describes the use of osmolytes for the production of a medicament, medical product or cosmetic product for the prevention, therapy and/or care of dry mucous membranes. The present invention relates to topical compositions based on osmolytes to which sodium chloride and/or moisturizers can optionally be added. The group of osmolytes proposed by the invention embraces various low-molecular substances, in particular ectoine, homoectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3-diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), β-mannosylglycerate (Firoin), β-mannosylglyceramide (Firoin-A), di-mannosyl di-inositol phosphate (DMIP), glucosylglycerol and/or a derivative, e.g. an acid, salt or ester, of these compounds. | 2010-11-25 |
20100297035 | Thiazole Amides, Imidazole Amides and Related Analogues - Thiazole amides, imidazole amides and related analogues of the Formula: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies). | 2010-11-25 |
20100297036 | PRESSURIZED COSMETIC COMPOSITION COMPRISING AT LEAST ONE ANIONIC POLYURETHANE ELASTOMER AND AT LEAST ONE PROPELLANT - Provided is a cosmetic composition packaged in an aerosol device comprising in a cosmetically acceptable medium, at least one film-forming anionic polyurethane elastomer and at least one propellant. Also provided is a method for shaping the hair comprising applying this cosmetic composition to the hair. | 2010-11-25 |
20100297037 | MATERIAL COMPOSITION FOR ORAL HYGIENE PRODUCT - The present invention relates to a material composition, particularly for an oral hygiene product suitable for combating caries and also for combating parodontitis and gingivitis. Said material composition or oral hygiene product is characterized in that it comprises an extract of Curcuma xanthorrhiza or xanthorrhizol and folic acid. | 2010-11-25 |
20100297038 | Benzimidazole Derivatives And Their Use As Cooling Agents - The present invention refers to compounds with cooling properties, the compound are of formula (I), | 2010-11-25 |
20100297039 | Oil-In-Water Emulsion Composition And Method For Producing The Same - The present invention provides an oil-in-water emulsion composition having excellent emulsion stability, low sticky feeling, and low skin irritation. The oil-in-water emulsion composition according to the present invention comprises (a) 1 to 20 mass % of a powder component, (b) 0.001 to 0.5 mass % of a cationic surfactant having two alkyl chains with 12 or more and 22 or less carbon atoms, (c) an oil phase component, and (d) a water phase component, having a structure that (a) powder particles are adsorbed on the oil droplets dispersed in the water phase, and containing substantively no surfactant other than the (b) cationic surfactant. | 2010-11-25 |
20100297040 | Cellular age advantage; nutrient reservoir cosmetic composition - In recent years the demand for cosmetic compositions and cosmetic methods for improving the appearance and condition of skin has grown enormously; consumers are seeking topical skin care products that help treat or delay the signs of natural (chronoaging) and environmental aging. The present invention relates to topical compositions for application to human skin and to their use in improving the condition and appearance of skin. It is based on the premise that effective treatment of normal skin conditions due to natural or environmental aging, such as wrinkles, lines, sagging, hyperpigmentation and age spots, and/or of sensitive, dry, rough, flaky, red, itchy, irritated skin may be obtained through the application of cosmetic compositions to the skin which comprise a combination of collagen stimulators, phytoestrogens, plant derived anti-inflammatory agents, fatty acid, antioxidants. | 2010-11-25 |
20100297041 | STABLE DISPERSIONS OF SOLID PARTICLES IN A HYDROPHOBIC SOLVENT AND METHODS OF PREPARING THE SAME - A method of dispersing a solid particles in a hydrophobic solvent is disclosed. The method utilizes an acrylate copolymer containing long siloxane chains to provide stable dispersions of solid particles in hydrophobic solvents having a solubility parameter of about 8 or less, such as a silicone fluid. | 2010-11-25 |
20100297042 | Cosmetic Compositions and Methods Comprising Rhodiola Rosea - A cosmetic composition comprising a UV-protective amount of at least one rosavin, preferably present in an extract of | 2010-11-25 |
20100297043 | SKIN COATING COMPOSITION AND USES THEREOF - A composition for coating skin comprising shellac, ethanol, castor oil, ethyl cellulose and fumed silica or nano zinc oxide, wherein the composition forms a long lasting waterproof flexible film on skin. The composition may include different ingredients for different applications. In one embodiment, the composition includes pigment and/or dye and may be used to coat a skin blemish such that the skin blemish blends in with the surrounding skin. In another embodiment, the composition includes a sunscreen agent and may be used as a sunscreen. In yet another embodiment, the composition includes a therapeutic agent for treating a disorder of the skin. | 2010-11-25 |
20100297044 | Emulsifier Mixture Containing Fatty Alcohols, Ethoxylated Fatty Alcohols and Oil or Wax Components - A cosmetic composition is provided consisting of (1) an emulsifier consisting of (a) about 0.002% to about 12% of one or more fatty alcohols, based on the cosmetic composition, (b) about 0.6% to about 19.4% of one or more ethoxylated fatty alcohols, (c) about 0.002% to about 4.0% of a component selected from the group consisting of dialkyl ethers, dialkylene ethers, dialkyl carbonates, dialkylene carbonates and mixtures thereof; and (2) one or more cosmetic components selected from the group consisting of fats, oils, waxes, humectants, hydrotropes, solubilizers, inflammation inhibitors, active principles, thickeners, plant extracts, anionic surfactants, cationic surfactants, amphoteric surfactants, zwitterionic surfactants, cationic polymers, silicones, superfatting agents, stabilizers, biogenic agents, glycerol, preservatives, dyes, perfumes, antiperspirant actives, UV protection filters and water. In another embodiment, the emulsifier component (1) also consists of (d) about 0.002% to about 2.0% of one or more partial glycerides. | 2010-11-25 |
20100297045 | EFFECT PIGMENTS BASED ON ARTIFICIALLY PRODUCED SUBSTRATES WITH A NARROW SIZE DISTRIBUTION - The invention relates to effect pigments comprising artificial platelet-shaped substrates which have at least one optically active coating, where the effect pigments have a volume-averaged cumulative undersize distribution curve with the characteristic numbers D | 2010-11-25 |
20100297046 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors - The invention relates to compounds and methods for inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin, by way of fructosamine-3-kinase inhibition, thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress. | 2010-11-25 |
20100297047 | ESTERS OF GLYCEROL AND THEIR USES IN COSMETIC AND PHARMACEUTICAL APPLICATIONS - The invention provides mixtures of tri-, di-, and mono-glycerides obtained by esterification of fatty acids from vegetal oils such as olive oil with glycerine, their production process and their use in cosmetic and pharmaceutical preparations, in particular as vehicle or solubiliser for active ingredients. | 2010-11-25 |
20100297048 | Use of Derivatives of 4-Hydroxyphenoxy Acetic Acid - The present invention relates to substances which can be used as cosmetic ingredients, especially for skin whitening and as cosmetic agents against signs of ageing skin. The present invention also relates to the use of such substances for the manufacture of a medicament for the treatment of disorders related to the pigmentation of the skin. | 2010-11-25 |
20100297049 | LIGHTENING AND/OR DYEING OF HUMAN KERATIN FIBRES BY MEANS OF A COMPOSITION COMPRISING A PARTICULAR AMINO SILICON COMPOUND AND COMPOSITION AND DEVICE - The present disclosure provides a method of lightening and/or colouring human keratin fibres using at least one first composition comprising at least one specific aminosilicon compound and at least one oxidizing composition. It also provides a composition containing less than 10% by weight of water comprising at least one specific aminosilicon compound and at least one fatty substance. It provides, lastly, a multiple-compartment device in which at least one compartment comprises the abovementioned composition, and at least one other compartment comprises an oxidizing composition. | 2010-11-25 |
20100297050 | COMPOSITIONS CONTAINING SILICONE POLYMER, WAX AND VOLATILE SOLVENT - The invention relates to compositions containing at least one polyorganosiloxane-containing polymer, at least one volatile non-silicone oil, at least one alkylene polymer wax, at least one silicone film-forming agent and, optionally, at least one long-chain alcohol wax, at least one coloring agent, and/or at least one volatile silicone oil, as well as to methods for using such compositions and to kits containing such compositions. | 2010-11-25 |
20100297051 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE ELASTOMERIC ANIONIC POLYURETHANE AND AT LEAST ONE NON-IONIC THICKENER - The present disclosure relates to a cosmetic composition comprising, in a cosmetically acceptable medium, at least one elastomeric anionic film-forming polyurethane and at least one non-ionic thickening polymer, as well as a hairdressing method for the shaping of the hair comprising the application of this composition. | 2010-11-25 |
20100297052 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE ELASTOMERIC POLYURETHANE - Provided is a cosmetic composition comprising, in a cosmetically acceptable medium, at least one film-forming elastomeric, anionic polyurethanes, as well as a method for the styling of the hair comprising applying this composition to the hair. | 2010-11-25 |
20100297053 | DEODERANT AND DEODERIZING PRODUCT - The invention provides a deodorant excellent in the deodorization performance against aldehyde gases such as acetaldehyde and formaldehyde and a deodorant having excellent deodorization performance even against various bad smells other than aldehyde gases. The invention has been accomplished on the basis of the finding that a mixture of an inorganic powder with an aminoguanidine salt has excellent deodorization performance against aldehyde gases. This mixture exerts deodorization performance in a wide temperature range. Further, it has been also found that a product obtained by heating the mixture is usable as a deodorant excellent in water resistance. Substrates containing the deodorant are suppressed in the emission of aldehyde gases from the substrates. That is to say, the invention relates to a deodorant against aldehyde gases consisting of a mixture which is composed of an aminoguanidine salt and an inorganic powder and whose aqueous suspensions have pH of 1 to 7. | 2010-11-25 |
20100297054 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS - The present invention relates to substituted triazole compounds of the formula (I): | 2010-11-25 |
20100297055 | COSMETIC COMPOSITION COMPRISING MULTIFUNCTIONALISED POLY (ALPHA OLEFIN-COPOLYMER-MALEIC ANHYDRIDE) - The present invention relates to cosmetic compositions comprising multiple functionalized maleic anhydride/α-olefin copolymers which have been functionalized with a first reactive —OH or —NH | 2010-11-25 |
20100297056 | COMPOSITION BASED ON PERHYDROSQUALENE AND COLLAGEN-POLYVINYLPYRROLIDONE FOR FILLING MINOR CUTANEOUS DEPRESSIONS - The present invention concerns a composition based on collagen-polyvinylpyrrolidone and perhydrosqualene for filling by intracutaneous delivery route minor depressions of the skin in order to enhance the appearance thereof without causing a negative immune reaction or rejection of the extraneous body, a method for preparing the composition and the use thereof in the prevention and treatment of minor depressions in the skin by means of a temporary mechanical effect thereby avoiding the encapsulation of the substance, since depending among various factors on time, some compositions eventually cause a reaction to the extraneous body, leading to inflammation of the treated area and fibrosis. The composition as per the invention has the characteristic of being prepared to a controlled alkaline PH and forms a stable emulsion without foam. | 2010-11-25 |
20100297057 | PESTICIDE COMPOSITIONS EXHIBITING ENHANCED ACTIVITY AND METHODS FOR PREPARING SAME - Pest controlling compositions exhibiting enhanced pesticidal activity levels and methods for preparing the same are disclosed. In one embodiment, a method includes providing a liquid composition that includes at least one pesticide and at least one co-ingredient that enhances pesticidal activity of the composition compared to a composition dissimilar only in not having the at least one co-ingredient. The at least one co-ingredient may include at least one metal oxide, a combination of at least one transition metal salt and at least one proteinaceous material or a combination of at least one proteinaceous material and at least one polymeric material. The method further includes spray drying the liquid composition to provide a solid composition. In one aspect of this embodiment, the solid composition provided by the spray drying exhibits enhanced pesticidal activity compared to the liquid composition. | 2010-11-25 |
20100297058 | PREBIOTIC COMPOSITION - The present invention provides for use of a composition comprising black tea flavonoids as a prebiotic and/or for the treatment or prevention of conditions associated with poor gut health or low immunity. The flavonoids comprise thearubigin in an amount of at least 82% by weight of the tea flavonoids. Also provided is an edible product comprising the black tea flavonoids. | 2010-11-25 |
20100297059 | METHODS AND COMPOSITIONS FOR CONTROL OF GYPSY MOTHS, LYMANRIA DISPAR - The invention provides in part dialkoxybenzene and eugenol compounds for controlling infestation by a | 2010-11-25 |
20100297060 | ENHANCEMENT OF ANTIBODY-CYTOKINE FUSION PROTEIN MEDIATED IMMUNE RESPONSES BY COMBINED TREATMENT WITH IMMUNOCYTOKINE UPTAKE ENHANCING AGENTS - Disclosed are methods and compositions for treating tumors. Disclosed methods and compositions enhance the uptake of immunocytokines into tumors, and are based on a combination of an immunocytokine with an immunocytokine uptake enhancing agent. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal. | 2010-11-25 |
20100297061 | STAT3 ANTAGONISTS AND THEIR USES AS VACCINES AGAINST CANCER - The present invention relates to methods for treating and/or preventing cancer. In particular the present invention relates to ex vivo immunotherapeutic methods. The methods comprise decreasing Stat3 (signal transducer and activator of transcirption3) expression and/or function in tumor cells and the administration of such cells to a subject in need of treatment and/or prevention. Other methods of the invention comprise activation T-cells by co-culturing the T-cells with the tumor cells with decreased Stat3 expression or function. The invention further encompasses methods comprising decreasing Stat3 expression or function in antigen-presenting cells and co-administering tumor cells and the antigen-presenting cells with decreased Stat3 function to a patient. The invention further relates to methods for stimulating dendritic cell differentiation. | 2010-11-25 |
20100297062 | Stable Formulations Of Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor - Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described. | 2010-11-25 |
20100297063 | CYTOKINE ZALPHA11 LIGAND ANTIBODIES - Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described. | 2010-11-25 |
20100297064 | CYTOKINE ZALPHA11 LIGAND ANTIBODIES - Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described. | 2010-11-25 |
20100297065 | HOMOGENEOUS PREPARATIONS OF IL-31 - Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. | 2010-11-25 |
20100297066 | BIODEGRADABLE PEPTIDE RELEASING POLYMERS - Novel biodegradable compositions are disclosed. The biodegradable compositions include at least one hydroxyl-terminated component and at least one bioactive peptide in a linear chain. The compositions may be utilized as medical devices including drug delivery devices, tissue adhesives and/or sealants. | 2010-11-25 |
20100297067 | METHYLATION MARKERS FOR PROSTATE CANCER AND METHODS OF USE - The present invention provides methods for identifying prostate cancer by detecting nucleic acid methylation of one or more genes in one or more samples. The invention further relates to DNA methylation as a predictor of prostate cancer recurrence and patient prognosis. | 2010-11-25 |
20100297068 | METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29 - IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections. | 2010-11-25 |
20100297069 | PEGYLATED INTERLEUKIN-10 - Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10. | 2010-11-25 |
20100297070 | COMPOSITIONS AND METHODS FOR AMELIORATING CNS INFLAMMATION, PSYCHOSIS, DELIRIUM, PTSD or PTSS - The invention provides compositions and methods for ameliorating, treating, reversing or preventing pathology or inflammation in the central nervous system (CNS), or the brain, caused or mediated by NFkB, IL-6, IL-6-R, NADPH oxidase (Nox), and/or superoxide and/or hydrogen peroxide production by a NADPH oxidase, including for example ameliorating, treating, reversing or preventing schizophrenia, psychosis, delirium, e.g., post-operative delirium, drug-induced psychosis, psychotic features associated with frailty syndrome (FS), aging, depression, dementias; traumatic war neurosis, post traumatic stress disorder (PTSD) or post-traumatic stress syndrome (PTSS), Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's Disease), and/or Multiple Sclerosis (MS). The invention also provides methods for purifying a C60 fullerene, C3 (tris malonic acid C60) or malonic acid derivatives. | 2010-11-25 |
20100297071 | IMMUNE RESPONSE INDUCER - An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s). | 2010-11-25 |
20100297072 | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy - A method comprising administering, to a mammal, an oncolytic virus and an immunostimulatory agent. A method of treating a first tumor, a second tumor, or both in a mammal having a first tumor, comprising administering an oncolytic virus into the first tumor; and administering an immunostimulatory agent systemically to the mammal. A kit comprising an oncolytic virus, an immunostimulatory agent, and instructions for administering the oncolytic virus and the immunostimulatory agent to a mammal. A kit comprising an oncolytic virus, an immunostimulatory agent, and instructions for treating a second tumor in a mammal having a first tumor by administering an oncolytic virus into the first tumor; and administering an immunostimulatory agent systemically to the mammal. The methods optionally include administering an additional anticancer therapy. | 2010-11-25 |
20100297073 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - Compounds having the formula I wherein | 2010-11-25 |
20100297074 | Wound healing compositions, systems, and methods - The present disclosure relates, according to some embodiments, to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-4 and IL-3 to enhance the differentiation of monocytes into fibrocytes. Methods and compositions for binding SAP, decreasing SAP levels and suppressing SAP activity are provided. Methods of using, inter alia, CPHPC, the 4,6-pyruvate acetyl of beta-D-galactopyranose, ethanolamines, high EEO agarose, IL-4, and IL-13, and anti-SAP antibodies and fragments thereof to increase monocyte differentiation into fibrocytes are provided. These methods are useful in a variety of applications, including wound healing. Wound dressings are also provided. Finally, the disclosure may include assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects. | 2010-11-25 |
20100297075 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER - The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent. | 2010-11-25 |
20100297076 | TARGETED INTERFERON DEMONSTRATES POTENT APOPTOTIC AND ANTI-TUMOR ACTIVITIES - This invention provides novel chimeric moieties that show significant efficacy against cancers. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-α). | 2010-11-25 |
20100297077 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF - The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation. | 2010-11-25 |
20100297078 | METHOD FOR PRODUCING A HYDROXYALKYL STARCH DERIVATIVE WITH TWO LINKERS - A method of producing a hydroxyalkyl starch (HAS) derivative, comprising a) reacting optionally oxidized hydroxyalkyl starch with a compound (D) comprising at least two functional groups —O—NH | 2010-11-25 |
20100297079 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION - The present invention describes compounds of formulae I and II and methods for treating viral infection, such as Flaviviridae virus infection, including Hepatitis C infection (HCV). | 2010-11-25 |
20100297080 | GENETIC MARKERS ASSOCIATED WITH INTERFERON-ALPHA RESPONSE - The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-α). These IFN-α response markers arc useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-α pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-α, and in methods for selecting the most appropriate therapy for such patients. | 2010-11-25 |
20100297081 | PHARMACEUTICAL FORMULATION CONTAINING RECOMBINANT HUMAN SERUM ALBUMIN-INTERFERON ALPHA FUSION PROTEIN - The present invention provides a pharmaceutical formulation containing a recombinant human serum albumin-interferon α fusion protein (rHSA-IFNα), said formulation is prepared by dissolving the fusion protein and a pharmaceutically acceptable stable excipient in a pharmaceutically acceptable buffer which pH ranges from 5.0 to 8.0. The recombinant human serum albumin-interferon α fusion protein concentration ranges from 0.1 mg/ml to 5 mg/ml. The stable excipient is glycine or methionine. The pharmaceutical formulation containing rHSA-IFNα has storage stability, which could act as immunomodulators for the treatment of viral infectious diseases, tumors and related diseases in the route of subcutaneous or intravenous administration. | 2010-11-25 |
20100297082 | WEIGHT-BEARING POLYURETHANE COMPOSITES AND METHODS THEREOF - Present inventions present composites of particles and polymers, as well as methods of making such composite and uses thereof. A low or non-porous composite comprises a plurality of bone particles; and polyurethane components with which the bone particles are combined. Provided composites can be prepared in a one-shot process. Alternatively or additionally, composites can be prepared by compression molding under a high pressure. Before or after implantation, provided composites may be set to form a hardened state of composites that provides mechanical strength and supports the in-growth of cells. | 2010-11-25 |
20100297083 | Polynucleotides and Polypeptide of Human KV1.3, Compositions Comprising Same and Methods of Using Same - An isolated polypeptide comprising, contiguously, a first amino acid sequence being at least 90% homologous to amino acid coordinates 1-398 of SEQ ID NO: 2, a tryptophan residue and a second amino acid sequence being at least 90% homologous to amino acid coordinates 400-523 of SEQ ID NO: 2. Also provided are polynucleotide sequences encoding this polypeptide and uses of same in the treatment of medical conditions associated with ion channel insufficiency. | 2010-11-25 |
20100297084 | METHOD FOR TRANSDUCING CELLS WITH PRIMARY CILIA - This invention provides methods for transducing a ciliated cell with a recombinant serotype 2 adeno-associated virus (AAV) vector. Additionally, the invention provides methods of treating diseases associated with a mutated gene by transducing a ciliated cell with a recombinant serotype 2 AAV vector containing a corrective transgene. | 2010-11-25 |
20100297085 | Synthetic Herpes Simplex Viruses Type-1 for Treatment of Cancers - A recombinant herpes simplex virus type-1 (HSV-1) has been constructed that carries a deletion of one of the two viral γ | 2010-11-25 |
20100297086 | Bacteriophage preparations and methods of use thereof - Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of | 2010-11-25 |
20100297087 | PLURIPOTENT STEM CELLS CHARACTERIZED BY EXPRESSION OF GERMLINE SPECIFIC GENES - The present invention relates to pluripotent or multipotent somatic stem cells characterized by the expression of the germline specific gene, DAZL. The somatic stem cells expressing the DAZL marker are further characterized by expression of additional markers and absence of expression of certain blood markers. In particular, the present invention discloses therapeutic and diagnostic uses, other than the germ cell potential use, of the DAZL pluripotent or multipotent stem cells isolated from adult or peripheral somatic sources such as peripheral blood, bone marrow or umbilical cord blood. | 2010-11-25 |
20100297088 | Methods for Culturing Minimally-Passaged Fibroblasts and Uses Thereof - The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times. | 2010-11-25 |
20100297089 | METHOD FOR PROMOTING THE SELF-RENEWAL OF ADULT STEM CELLS USING MESENCHYMAL STROMAL CELLS - The present invention relates to a composition for promoting the self-renewal of adult stem cells, comprising β-catenin or notch ligand-overexpressed mesenchymal stromal cells. Further, the present invention relates to a method for promoting the self-renewal of adult stem cells by co-culturing adult stem cells with the mesenchymal stromal cells. Furthermore, the present invention relates to β-catenin or notch ligand-overexpressed mesenchymal stromal cells for promoting the self-renewal of adult stem cells. | 2010-11-25 |
20100297090 | HEMATOPOIETIC CELL CULTURE NUTRIENT SUPPLEMENT - The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells. | 2010-11-25 |
20100297091 | COMPOSITIONS AND METHODS FOR TREATMENT OF MELANOMAS - In certain embodiments, an expression construct is provided that contains a tissue-specific promoter such as tyrosinase linked to one or more cytotoxin genes. The cytotoxin genes may be saporin genes. In certain embodiments, a vector is provided that contains an expression construct as discussed above. The vector may be an adeno-associated virus or an adenovirus. Further, neural stem cells may be provided that contain and/or produce a vector, which in turn contains an expression construct containing a tissue-specific promoter linked to one or more cytotoxin genes. In certain embodiments, methods of using the neural stem cells provided herein for production and delivery of an animal virus vector are provided. Methods for treating melanomas in a subject in need thereof are also provided by delivering an expression construct that contains a tissue-specific promoter linked to one or more cytotoxins. In certain embodiments, the melanoma is metastatic, and in certain embodiments the melanoma is a brain melanoma. | 2010-11-25 |
20100297092 | Inactivated Bacterial Cell Formulation - The invention relates to the use of lactic acid-producing bacteria to boost the immune system. | 2010-11-25 |
20100297093 | MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS - The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with one or more amino acid substitutions in the CDR2 and/or CDR3 regions of the alpha and/or beta chains of the TCR, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4 | 2010-11-25 |
20100297094 | THERAPY OR PREVENTION OF DISEASES WITH CELLS OR CELL SUPERNATANT - Methods and compositions for the treatment or prevention of diseases or disorders including media conditioned by mesenchymal stem cells and BCL2A1 are provided. Methods for the production of therapeutic or preventative compositions contacted with BCL2A1 are also provided. | 2010-11-25 |
20100297095 | Porifera-Based Therapeutic Compositions for Treating and Preventing Skin Diseases - Therapeutic compositions and methods for using same for treating skin conditions and diseases are disclosed. Treatable skin conditions and diseases include without limitation acne vulgaris, rosacea, seborrheic dermatitis, eczema (atopic dermatitis), psoriasis, photo-aging and actinic keratosisacne vulgaris, psoriasis, photo-aging and eczema. Therapeutic compositions disclosed are derived from Porifera species, specifically sponges, and more specifically fresh water sponges. One disclosed embodiment is derived from | 2010-11-25 |
20100297096 | AMPHIPHILIC PEPTIDE MATRICES FOR TREATMENT OF OSTEOPOROSIS - The present invention provides methods for prevention, prevention of progression, and treatment of osteoporosis and pre-osteoporotic conditions comprising direct administering to osteoporetic bone of a composition comprising amphiphilic peptides and peptide matrices thereof, useful in promoting biomineralization, local osteoporetic medications and inducing bone repair. | 2010-11-25 |
20100297097 | COMPOUNDS - The present invention relates to substituted triazole compounds of the formula (I): | 2010-11-25 |